In order to invent a screening system to check in vivo gene function and the efficiency of gene transfer mediated by a retroviral vector system, we established a novel packaging cell, PacC6/A8, that is transplantable to rat brains. The packaging cell is based on the gene of the neuropatogenic retrovirus, A8-V. For expression in the brain, a vector that expresses brain-derived neurotrophic factor (BDNF) tagged by c-Myc-His 6 (LxA/bdmh) was constructed. After transfection of LxA/bdmh to PacC6/A8, a cloned cell line, PacC6/ A8/bmh, was established. PacC6/A8/bmh cells stably produced pseudotyped retroviruses carrying LxA/ bdmh. For a control, a retroviral vector that bears the gene that codes enhanced green fluorescent protein (EGFP) tagged by C-Mic-His 6 was also created and used for the establishment of PacC6/A8/gfmh cells that produce pseudotyped retroviruses carrying LxA/gfmh. PacC6/A8/bmh and PacC6/A8/gfmh cells were injected to the brain of newborn rats. A tumor was formed in all the rats injected that did not exhibit any symptoms until 3-4 weeks after the injection. A histological study of the injected rats revealed that the transferred BDNF gene was expressed in the brain of rats injected with PacC6/A8/bmh cells, but not in rats with PacC6/A8/gfmh cells. Interestingly, many activated microglia had migrated into the tumor induced by PacC6/A8/bmh cells, and expressed a high amount of BDNF.
INTRODUCTION
trial experiments, we recognize the stability and efficacy of gene expression or gene transfer that varies depend-Improvement of the methods for studying in vivo exing on the inserted gene, 5′ leader sequence of the vecpression of extrinsically introduced genes to overcome tor, promoter function, origin of packaging cells, target the circumscription in transgenic animals produced by organs, or interaction of each gene utilized in the vector gene manipulation is of great interest to the clinico-medsystem. ical field as well as more basic scientific fields (9). The Therefore, it would be beneficial to establish a screenretroviral vector system is one of the most useful tools ing system for in vivo expression of genes of interest mefor these studies, especially in the central nervous sysdiated by retroviral vectors before utilizing such a complitem (CNS), due to its stable gene expression and low cated and expensive experimental system as the method toxicity and antigenicity. Despite these utilities, this vecusing a microencapsulation technique. In the present artitor system has a crucial disadvantage in that the vector cle we describe a simple method for testing the retroviral system produces relatively low titers of pseudoviruses vector function in vivo, constructing a packaging cell line to transfer genes through direct infection to the brain. derived from C6/G (20) that is transplantable into rat An implantation of microencapsulated (1) packaging brains. The C6/G cell line expresses GFAP, a marker procells to an appropriate point in the brain would improve tein of astrocytes, and was established in our laboratory the relatively low efficacy of gene transfer by means (20) after limiting dilution of rat glioma cell line C6. of a retroviral vector system with lower production of C6/G cells grow slowly, forming a tumor mass in the pseudoviruses than vectors based on the adenoviral brain after an injection of the cells into newborn rats. The gene, but the retroviral vector-mediated gene transfer injected rats survive without any symptoms for 3-4 system is still empirical on the present background of weeks. The gene-manipulated C6/G, PacC6/A8, a novel science. Only after construction of the vector system and packaging cell based on the C6/G and the neuropatho- genic virus A8-V gene (19) , exhibited the same trans-adenylation signal, but does not have the packaging signal [pA8(Ψ-)δ-BSD]. In order to select stable trans-plantability into rat brains as the original C6/G.
For an expression in the brain mediated by the retro-formants, the blastocidin deaminase (BSD) gene was introduced into the vector (Fig. 1b ). This construct was viral vector system, we chose the brain-derived neurotrophic factor (BDNF) gene. BDNF is a member of the transfected into the C6/G cell line (20) by calcium phosphate coprecipitation. Drug-resistant cells were selected neurotrophin (NT) family, which includes nerve growth factor (NGF) and NT-3, NT-4/5, and NT-6 (7). The im-in the medium containing 1.25 mg/ml of blastcidin (Invitrogene) and cloned (PacC6/A8). A retrovirus vector, portant role of BDNF has been firmly established in regulating the survival and differentiation of various neu-LxA/bmh or LxA/gfmh, was transfected into the PacC6/ A8, with Lipofectamine 2000 (Gibco BRL). Drug-resis-ronal populations including sensory, cerebellar, and spinal motor neurons (7). Neurons are the major source tant cells were selected and cloned in the medium containing 0.4 mg/ml of zeomycin (Invitrogene) and/or 0.8 of BDNF in the nervous system (4,7). It is thought that BDNF and NT-4/5 exert their biological function via the mg/ml G418 (Gibco BRL), and PacC6/A8/bmh and PacC6/A8/gfmh were obtained. The viral titers of the full-length form of trkB receptor, called gp 145 trkB (5), the expression of which seems to be restricted to the culture supernatant of PacC6/A8/bmh and PacC6/A8/ gfmh cells were 2.3-5.3 × 10 4 and 0.6-1.2 × 10 4 CFU/ neuronal cell population (8).
Several studies have shown that the administration of ml, respectively. BDNF protein or the BDNF gone can rescue injured or Immunoblots degenerating neurons and induced axonal outgrowth and Cell lysates of PacC6/A8/bmh were analyzed. Nonregeneration (2,6,10,17,21). Furthermore, BDNF had transfected C6/G and PacC6/A8/gfmh cells were used as beneficial effects in several animal models of neurocontrols. Cell lysates corresponding to 5 × 10 4 cells per degenerative disease (12) . These observations validate lane were subjected to 10% SDS-polyacrylamide gel BDNF administration as a human therapy for some deelectrophoresis and transferred to PVDF membranes generative neurological disorders. However, it has so far (Millipore). After blocking the membranes were incunot been possible to apply BDNF for the treatment of (1:5000, Promega), binding of secondary antibodies was molecular clone of the neuropathogenic Friend murine detected with 0.1 M Tris-HCl (pH 9.5) containing 0.1 leukemia virus, was subcloned into pBluecript II SK + M NaCl, 5 mM MgCl 2 , nitroblue tetrazolium (0.33 mg/ (Stratagene). Then 5′-LTR and packaging signal of ml), and 5-bromo-4-chloro-3-indolyl phosphate p-tolu-pLXSN (11) were inserted to the upstream of 3′-LTR of idine salt (0.165 mg/nl). A8, followed by insertion of neomycin resistance (neo) gene and CAG promoter, donated by Dr. Miyazaki (15) , Cell Transplantation and Histochemical Analysis to the downstream of the packaging signal sequence Lewis rats were purchased from a commercial (Fig. la) . Mouse BDNF cDNA (kindly provided by breeder. Newborn rats were injected intracerebrally with Dr. Nomoto, Gifu Pharmaceutical University, Japan) or 10 5 cells suspended in 1 µl of medium per head. Three the coding region cDNA of enhanced green fluorescent or 4 weeks after transplantation of the cells, the rats protein (EGFP) derived from EGFP-N1 vector (Clonwere deeply anesthetized with pentobarbital (75 mg/kg, tech) was inserted into the pcDNA3.1/Myc-His vector A IP) and perfused via the left cardiac ventricle with 2 ml (Invitrogen) after removal of the stop codons of BDNF of PBS, followed by 250 ml of 4% paraformaldehyde and EGFP genes. The coding regions of the tagged in 0.12 M phosphate buffer (pH 7.3). The brains were BDNF and EGFP genes were subcloned into the pLxA postfixed in the same fixative overnight, and were proviral vector (pLxA/bdmh and pLxA/gfmh, respectively) cessed for paraffin or frozen sections as previously de- (Fig. 1a) .
scribed (20) . For immunohistochemical analysis, anti-Generation of Pseudovirus-Producing Cells BDNF (polyclonal antibody, Santa Cruz), anti-c-Myc (monoclonal antibody clone 9E10), anti-gp70 (Quality An expression vector for Gag, Pol, and Env protein of A8-V was constructed. The vector contains LTR, gag, Biotech Incorporated, Resource Laboratory), anti-CD11b (Serotec), and anti-GFP (polyclonal antibody, pol, and the env gene of A8-V with the SV40 early poly- 1:500, Clontech) were used. The dewaxed paraffin sec-conjugated rabbit anti-mouse IgG (Molecular Probes) were used, depending on the first antibodies used. tions or frozen sections were treated with blocking sera containing PBS, 40% horse serum (Hatzelton), and 10% RESULTS AND DISCUSSION normal rat or mouse serum, depending on the first anti-Characterization of c-Myc-His 6 -Tagged BDNF body used. The sections were incubated with antibodies (dilution of antibodies described above) for respective
The vectors used in this study, LxA/bdmh and LxA/ gfmh, encoded mouse BDNF and EGFP, respectively antigens followed by biotinylated IgG depending on the first antibody used and then avidin-peroxidase complex (Fig. 1) . Each protein was tagged with c-Myc-His 6 . The tagged BDNF can be distinguished from the endogenous (Wako). The peroxidase activity was visualized with 0.1 mg/ml 3,3′-diaminobenzidine tetrahydrochloride and BDNF when it is expressed in the brain. BDNF should be secreted in the culture supernatant 0.003% H 2 O 2 in 0.1 M Tris-HCl buffer (pH 7.6). For the double immunodetection, FITC-conjugated anti-rabbit from the cultured BDNF-producing cells when it is correctly processed (3,18). We thus collected the superna-IgG (Sigma), Alexa Flour TM 594-conjugated goat antimouse IgG (Molecular Probes), and Alexa Flour TM 594-tant from the COS-7 cells transiently transfected with the BDNF-c-MyC-His 6 expression vector, and performed of BDNF ( Fig. 2a, b) . The introduced gene expression was detected also in the brain tissue outside of the tu-Western blot analysis with an anti-BDNF or anti-c-Myc antibody.
mor. Figure 2e shows the human c-Myc-His 6 expression in the hypothalamus of rat/bmh. Activation of microglia The culture supernatant and cell lysate of the COS cells transfected with the expression vector for BDNF-c-in rat/bmh might be induced by transduced BDNF because microglia express the BDNF receptor, trkB (14) . Myc-His 6 contained BDNF-immunoreactive bands with relative molecular masses of approximately 33 (double Gene transfer to microglia in the brain is beneficial for medical application of the vector system, because micro-bands) and 17 kDa, which were absent from the culture supernatant and cell lysates of untransfected COS cells glia migrate to the pathological lesions where they can secrete BDNF to protect the neurons (17). and the cells transfected with pEGFP-c-Myc-His 6 . The 33-kDa double bands correspond to unprocessed pro- ted C6/G cells (data not shown).
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